TRPA1 in Drug Discovery

Part of the Methods in Pharmacology and Toxicology book series (MIPT)


TRPA1 is one of the few ion channels with human genetic validation for pain. A TRPA1 gain-of-function mutation is linked to familial episodic pain syndrome in humans. This milestone discovery, coupled with a growing preclinical literature implicating TRPA1 in multiple indications, has made TRPA1 an attractive therapeutic target. With extensive investment across the pharmaceutical industry, several novel nonreactive TRPA1 antagonist series have emerged in patents, and two TRPA1 compounds have recently advanced to human clinical trials. A review of the diverse roles for TRPA1 in pain signaling and other indications such as itch and respiratory diseases is presented along with an overview of known small molecule activators and antagonists of the TRPA1 receptor.

Key words

TRPA1 antagonists Pain Respiratory disease Overactive bladder Itch 

1 Introduction

TRPA1, also known as ANKTM1 and p120, belongs to the transient receptor potential (1) superfamily, which consists of a large group of cation channels present in species from yeast to mammals (2, 3). In mammals, there are 28 members from six subfamilies (TRPC, TRPV, TRPM, TRPML, TRPP, and TRPA), playing critical roles in physiological processes ranging from vasorelaxation, fertility, cell growth to sensory function. TRPA1 is the only member of the TRPA subfamily, and distinctively different from other TRP channels with an overall low sequence homology (<40% in transmembrane domains), a large N terminus containing many ankyrin repeat domains (ARD), and sensitivity to a variety of stimuli. Activation of TRPA1 leads to membrane depolarization and increase in intracellular Ca2+ which initiate multiple downstream signaling cascades that ultimately control a variety of physiological processes.

1.1 Expression

Although TRPA1 was originally cloned from cultured human lung fibroblasts, it is most predominantly expressed in primary sensory neurons where it co-localizes with pain markers and peptidergic nociceptors (e.g., TRPV1, CGRP, substance P, and bradykinin receptors) (4, 5, 6, 7). Among acutely dissociated DRG neurons, 30% respond to TRPA1 agonists (8). TRPA1 expression level is increased in rodent models of inflammatory and neuropathic pain, as well as in avulsion-injured human DRG (4, 6, 9, 10). Furthermore, TRPA1 expression is increased by nerve growth factors and nociceptive signals (4, 11). Besides its predominant expression in sensory neurons, TRPA1 has been reported to also be expressed in nonneuronal cells and tissues, including skin (12), inner ear (13), urinary bladder (14, 15), stomach (16), and cerebral arteries (17).

1.2 Structure–Function

A functional TRPA1 channel is predicted to be formed by four subunits each consisting of six transmembrane domains, a pore domain between helices 5 and 6, and large intracellular segments of cytoplasmic N- and C termini (Fig. 1). This overall architecture was recently confirmed by a 16 Å resolution electron microscopy structure of mouse TRPA1 (18). TRPA1 is a nonselective cation channel that can open or close in response to conformational changes induced by binding of reactive or nonreactive ligands, changes in levels of intracellular Ca2+, or by other modifications of the protein. Specific domains and amino acids that play an important role in channel gating have been identified by site-directed mutagenesis.
Fig. 1.

TRPA1 structural scheme and domains critical for function. See text for abbreviation.

TRPA1 is activated by electrophilic compounds such as allyl isothiocyante (AITC) through covalent modification. Several cysteine and lysine residues in the N terminus have been identified as covalent modification sites, including C415, C422, and Cys622 in mTRPA1 and C621, C641, C665, and K711 in hTRPA1 (NM_007332) (19, 20). The quadruple mutation in hTRPA1 (C621S/C641S/C655S/K711Q) was found to reduce, but did not eliminate AITC sensitivity, indicating contributions from other yet unidentified residues (21). Another observation is that only one residue is in equivalent position of human and mouse channels (e.g., C622 in mTRPA1 and C621 in hTRPA1), suggesting that covalent modification may differ across species.

TRPA1 contains a large number (at least 12) of ARD in its N zterminus. ARDs are responsible for the difference in heat sensitivity between Drosophila TRPA1 and hTRPA1, and these domains are also involved in modulating sensitivity to chemical irritants and cytosolic Ca2+ (22). The complex regulation of TRPA1 channel gating that is mediated by changes in intracellular Ca2+ has been shown to involve several different structural domains. Cytosolic Ca2+ activates the channel by binding to residues of an EF-hand domain in the N terminus (e.g., S468 and T470 in human TRPA1) (23, 24). Permeation Ca2+ ions potentiate, and then desensitize the channel through binding to an acid residue in the putative selectivity filter (D918 in rat TRPA1) (25). Several residues in the S5 domain (S876/T877 in mouse TRPA1) were identified as critical sites for menthol binding (26). In a previous study, we found that thioaminals covalently modified channel proteins but produced species-specific effects: activation of rat TRPA1, but block of human TRPA1. The opposite gating was attributed to residue difference in several S6 residues: A946 and M949 in rat TRPA1 were shown to be responsible for channel activation, and equivalent residues in human TRPA1 (S943 and I946) resulted in channel block (21). Therefore these residues may constitute a part of the gating machinery of TRPA1.

2 TRPA1 Activators

The most striking property of TRPA1 is its activation by a plethora of stimuli, including electrophilic agonists, nonelectrophilic agonists, and physiological stimuli. This property fulfills its role as a broad chemosensor to changes in external and internal environment.

2.1 Electrophilic Agonists

Many electrophilic compounds present in pungent natural products or chemical irritants activate TRPA1 by reacting with nucleophilic residues in the channel (Fig. 2). Some of the natural products that have shown to activate TRPA1 include allyl isothiocynate (AITC) from mustard oil, cinnamaldehyde from cinnamon, allicin from raw garlic, and isovelleral from the fungus Lactarius vellereus (Fig. 2) (5, 27, 28). Their pungency and deterrent power are largely mediated through TRPA1 (29). Additionally, TRPA1 can be activated by a large number of reactive environmental irritants, such as acrolein from cigarette smoke, isothiocyanates from industry waste, CN from tear gas, acetaldehyde from alcohol, hyperchlorite from bleach, and ozone from air pollutants (29, 30, 31, 32). In spite of their different structures and origins, these compounds are all electrophilic and activate TRPA1 through a common mechanism, covalent modification of key cysteine, and lysine residues localized in the N terminus of the channel (Fig. 1) (19, 20, 33). An increasing number of potential endogenous ligands have also been identified, including lipid peroxidation products (e.g., 4-hydroxynonenal), cyclopentenone prostaglandin metabolites (e.g., 15-d-PGJ2), and reactive oxygen species (e.g., H2O2 and nitric oxide) and reactive nitrogen species (nitric oxide) (34, 35). These molecules have the potential to nonselectively modify proteins, but their proalgesic and pro-inflammatory effects are largely attributed to TRPA1.
Fig. 2.

TRPA1 agonists.

2.2 Nonelectrophilic Agonists

An increasing number of structurally diverse, nonreactive TRPA1 agonists have also been identified, including arachidonic acid, URB597, farnesyl thiosalicylic acid, trinitrophenol, flufenamic acid, d-9-THC, 2-APPB, diclofenac, isoflurane, and PF-4840154 (Fig. 2) (27, 36, 37, 38, 39, 40). The apparent lack of chemical reactivity suggests that they activate TRPA1 through noncovalent interactions, but the exact mechanism has not been elucidated.

2.3 Physiological Stimuli

Physiological stimuli that activate TRPA1 include changes in intracellular Ca2+, hypertonicity, and arguably noxious cold. Ca2+ is an important regulator of TRPA1 function and has complex effects: intracellular Ca2+ directly activate TRPA1 via binding to an N-terminal EF-hand domain (24); while permeating Ca2+ potentiates and desensitizes the channel (25). Hypertonicity activates both recombinant and native TRPA1 in DRG neurons, implicating a possible role of TRPA1 in mechanosensation (41). Bradykinin activates TRPA1 indirectly through the phospholipase C pathway, and its nociceptive effect is reduced in TRPA1-deficient mice (27, 29). TRPA1 can also be activated downstream of Mas-related G protein-coupled receptors, which mediated histamine-independent itch (42). It was reported originally that noxious cold activated TRPA1 (4), but this issue remains controversial (43, 44).

3 Antagonists

To date, several antagonists (HC-030031, AP18, A-967079, and Chembridge-5861528) have been utilized as tools for probing TRPA1 function and therapeutic utility (45, 46, 47, 48, 49). The broad interest in TRPA1 antagonists is noted by the large number of patents filed in recent years (>20 patents since 2007).

3.1 Electrophilic Antagonists

Covalent modification is the most important mechanism for TRPA1 activation, but not all electrophilic compounds are TRPA1 agonists. Amgen and Abbott have independently identified a series of reactive, thioaminal containing compounds that function as human TRPA1 antagonists (Fig. 3) (21, 50). The blocking effect is dependent on the electrophilic nature of the compounds, since removing the reactive sulfur atom of the compounds or the key cysteine residues in the channel abolishes inhibition. Interestingly, the same compounds activate the rat channel. Therefore, covalent modification can lead to different functional consequences; whether channels open or close depends not only on their respective proteins (e.g., rat and human TRPA1), but also on the nature of specific chemical adducts formed by electrophilic compounds. These compounds are useful tools in studying TRPA1 structure–function, but the species-specific effects limit their potential for advancement.
Fig. 3.

Electrophilic antagonists.

In contrast to thioaminals, compounds from an oxime series have more consistent effects across species (46, 49, 51). AP18 was the first reported antagonist within this series, with IC50 of 3.1 μM and 4.5 μM on human and rat TRPA1, respectively (46). Abbott independently identified the same chemotype from a high throughput screen (52). Subsequent medicinal chemistry efforts led to the identification of oxime A-967079 (IC50: 67 nM on hTRPA1 and 290 nM on rat TRPA1) that represented the first potent and selective TRPA1 antagonist that demonstrated good oral bioavailability (51). Although the α, β-unsaturated oxime functionality could potentially react with nucleophiles, neither AP18 nor A-967079 was found positive in a battery of reactivity assays including glutathione assay, La antigen-based ALARM NMR or ALARM-MS (51). Furthermore, block of TRPA1 by A-967079 was reversible. Taken together, these data suggest that some oximes may not covalently modify the channel, or that they could covalently modify the channel but in a rapidly reversible manner.

3.2 Nonreactive Antagonists

3.2.1 Naturally Occurring Antagonists

Several natural products exhibit inhibitory effects on TRPA1 (Fig. 4). Caffeine suppresses human TRPA1 activity at millimolar concentrations (1). Although it is relatively weak and it activates, rather than blocks mouse TRPA1, caffeine has served as an important starting point for the construction of potent TRPA1 antagonists described in patents from Hydra and Glenmark. Menthol blocks mouse TRPA1 at high concentrations (e.g., 300 μM) and activates at lower concentrations (e.g., 10 μM). It exhibits only an agonist effect on human TRPA1 across a range of concentrations (26). It will be interesting to explore whether menthol can be used as a building block for the discovery of future potent antagonists. Resolvin D1, a naturally occurring anti-inflammatory lipid, blocked mouse TRPA1 with IC50 of 69 nM (53). In behavioral testing, Resolvin D1 blocked nociceptive responses evoked by cinnamaldehyde and formalin. Interestingly, Resolvin D1 is even more potent in inhibiting TRPV3 and TRPV4 (IC50: 28.9 nM and 8.1 nM, respectively). It is not clear whether Resolvin D1 interact with these channels directly or through an indirect mechanism. Nonetheless, these results suggest the existence of endogenous TRPA1 antagonists.
Fig. 4.

Natural antagonists.

3.2.2 Pharmaceutical Nonelectrophilic Antagonists

Hydra Biosciences was the first to patent potent TRPA1 antagonists that incorporate the xanthine alkaloid core that is present in caffeine (Fig. 5). Building off the purine core at the N7 methyl group with an arylated amide functionality led to significant gains in TRPA1 potency (HC-030031 IC50  <  5–20 μM, WO2007073505). Further manipulation by changing the aryl group from phenyl to thiazole, and appending a second aryl functionality attached to aliphatic pyrrolidine capping group led to exceptionally potent TRPA1 antagonists (Example 1 IC50 4 nM, WO2010/075353). Transposition of the lipophilic side chain to the C8 position of the purine heterocycle also leads to TRPA1 antagonists of reasonable potency (Example 1 IC50 497 nM, WO2010/132838).
Fig. 5.

Hydra antagonists.

Glenmark Pharmaceuticals also filed patents for TRPA1 antagonists based on the caffeine xanthine alkaloid core (Fig. 6). The Glenmark approach has been focused on modification of the xanthine ring to create several new classes of TRPA1 antagonists. Reversal of the 6-5 purine core to a 5-6 phthalimide system maintained TRPA1 potency (Example 17 IC50  <  250 nM, WO2009/118596). In addition, replacement of the bicyclic purine core with the tricyclic imidazopurinone maintains potency at TRPA1 (Example 8 IC50  <  500 nM, WO2009/144548). TRPA1 potency is also maintained when the five membered imidazole fragment of the purine core is replaced with a variety of different heterocycles, including phenyl (US2009325987), isothiazole (WO2010/109328), pyrrole (WO2010/109287), thiophene (WO2010/109334), pyridine (WO2010/004390), and imidazolone (WO2011/114184).
Fig. 6.

Glenmark antagonists.

TRPA1 antagonists featuring greater structural diversity have been reported by Janssen and Merck (Fig. 7). Janssen has described a class of highly potent biaryl pyrimidines that contain a pyrrolidine carboxamide side chain (Example IC50 3 nM, WO2010/141805). They have also described a second lead series based on the tricyclic thioxodihydroindenopyrimidinone core (Compound 29 IC50 13 nM, WO2009/147079). Merck has described a lower molecular weight lead series based on a hydroxy-substituted aminodecalin core (Example, IC50 19 nM, WO2011/043954). This lead series demonstrates more attractive drug-like properties (MW 263, cLog P 4.1) than many previously described antagonists.
Fig. 7.

Janssen and Merck antagonists.

4 TRPA1 Involvement in Pain

Evidence for TRPA1 contributions to pain starts with the observation that local application of “natural” TRPA1 agonists trigger spontaneous pain in humans (54) and induce nocifensive behaviors in animals (29). TRPA1 is expressed in small- and medium-sized peptidergic primary afferent somatosensory neurons that express TRPV1 and receptors for calcitonin gene-related peptide, substance P, and bradykinin, which are key mediators/transmitters in nociceptive signaling (5, 7, 29). TRPA1 expression is increased in these sensory neurons in humans with an avulsion injury as well as in animal models of neuropathic and inflammatory pain (7, 10). Recently, a gain-of-function mutation in TRPA1 was linked to familial episodic pain syndrome in humans, providing strong validation of TRPA1 in human pain states (55).

4.1 Chemical Nociception

TRPA1 is a key chemosensor for many pungent natural products and environmental irritants including AITC from horse radish, cinnamaldehyde from cinnamon, allicin from garlic, acrolein from cigarette smoke, and ozone from air pollutants (56, 57). These agents trigger tissue irritation and a burning sensation. TRPA1 is activated indirectly by bradykinin, a mediator of neurogenic inflammation (27). In behavioral experiments, TRPA1−/− mice lost aversion to oral AITC, and had diminished nocifensive responses to hind paw injection of AITC and intraplantar bradykinin (29, 58).

4.2 Mechanical Nociception

Gene ablation (TRPA1−/−) studies have examined TRPA1 contributions to mechanical nociception. In uninjured rats, mechanical thresholds were not different between wild type and knockout animals, nor was there an impairment in the development of mechanical hyperalgesia after an inflammatory injury (46, 59). However, mechanical sensitization typically induced by mustard oil injection was not observed in TRPA1−/− mice (59), and a TRPA1 antagonist (AP18) did not reduce mechanical hyperalgesia in inflamed knockouts despite effectiveness in wild types (46). Mechanically activated currents in small diameter primary afferent neurons were also significantly reduced in amplitude in TRPA1−/− animals compared to wild types (60). Another study demonstrated that TRPA1−/− animals had less sensitivity to low-intensity mechanical stimuli compared to wild-type mice, and responses to high-intensity (noxious) mechanical stimulation were appreciably impaired (58). Hypertonic solutions were also found to activate recombinant and endogenously expressed rat TRPA1 (41); Taken together, a possible role for TRPA1 in mechanotransmission was suggested by these studies.

Using the skin-nerve preparation, it was found that TRPA1 in normal skin are necessary for mechanotransmission in several types of primary afferent fibers including slowly adapting C-fibers, Aδ-fiber mechanonociceptors, and slowly adapting Aβ-fibers (61). HC-030031 did not alter the responses of C- and A-fibers to low-intensity mechanical stimulation of normal skin (62); however, it reduced the responsiveness of C-fibers once the stimulus force was increased into the high-intensity range. Similarly, with an in vivo preparation, systemic administration of A-967079 reduced the responses of spinal wide dynamic range (WDR) and nociceptive specific neurons to high-intensity mechanical stimulation in uninjured rats as well as in rats with an osteoarthritic (OA) or inflammatory injury (49). In contrast, the transmission of low-intensity mechanical stimulation was impeded by A-967079 only following an inflammatory injury and was not altered in uninjured animals. The combined data suggest that TRPA1 factors into high-intensity mechanotransmission under both normal and pathological conditions, but shifts to include lower intensity stimulation following an inflammatory injury. The lowering of mechanical thresholds could be linked to TRPA1 up-regulation and/or sensitization by inflammatory mediators such as bradykinin and prostaglandins (27, 33).

The physiological data underscore effects of TRPA1 antagonists on mechanical sensitivity in behavioral assays. Responses to mechanical stimuli in inflamed and neuropathic rats were decreased by systemic administration of HC-030031 and Chembridge-5861528 (47, 48, 63). Intraplantar injection of AP18 attenuated mechanical hyperalgesia in wild type but not in knockout mice (46). Intrathecal delivery of A-967079 or Chembridge-5861528 attenuated secondary mechanical sensitivity following capsaicin or formalin injection (64). However, these data are contrasted by the observations that A-967079 did not attenuate mechanical hypersensitivity in models of neuropathic and inflammatory pain, and TRPA1-specific antisense oligodeoxynucleotides. Thus, although the majority of data points to a role for TRPA1 in mechanosensation in uninjured and sensitized states, some inconsistencies still need to be explained.

4.3 Cold Nociception

The role of TRPA1 in noxious cold sensation is highly controversial (43, 44). Channel activation by noxious cold has been reported in several studies (4, 65), but has been disputed or attributed to an indirect intracellular Ca2+-mediated mechanism (5, 24). TRPA1-deficient mice were shown to be less responsive to acetone-mediated evaporative cooling, cold plate, and tail immersion than wild-type animals (58, 65); while other studies showed normal cold sensitivity in knockout mice (29, 66). Injection of A-967079 or HC-030031 did not produce deficits in the cold plate test in uninjured mice, but attenuated cold allodynia in models of neuropathic pain (51, 67). HC030031 also reversed paclitaxel-mediated cold hyperalgesia in diabetic rats, and this effect may have been related to the increased expression of TRPA1 that was triggered by the overproduction of mitochondrial H2O2. TRPA1-specific antisense oligodeoxynucleotides were efficacious in attenuating cold allodyia in inflammatory and neuropathic pain models (7). These data suggest that TRPA1 plays a role in cold allodynia under disease states. It has also been suggested that TRPA1 may play a role in cold sensing in visceral sensory neurons, but not in cutaneous nociceptors (68, 69).

4.4 Heat Nociception

TRPA1 is not considered a heat-activated channel and thus there are limited studies in this area. Genetic ablation of TRPA1 or antagonism of the receptor with HC-030031 does not alter responses to noxious heat stimulation in uninjured animals (47, 58). However, HC-030031 was found to decrease thermal hyperalgesia in the paclitaxel model of chemotherapy-induced neuropathic pain (63). Interestingly, HC-030031 also reduced cold and mechanical hypersensitivity in this model, and this effect was likely mediated through proteinase-activated receptor 2 (PAR2)-related sensitization of neurons containing TRP receptors including TRPA1 (63). Additionally, injection of TRPA1 agonists enhances WDR neuronal responses to heat stimulation in naive rats (70, 71). This effect may not be surprising since topical application of AITC or CA can trigger burning pain and thermal hyperalgesia, which could be attributed to indirect sensitization of TRPV1 (54).

4.5 Spontaneous Nociception

In addition to effects on evoked stimulation, evidence suggests that TRPA1 may be involved in nonevoked discomfort or pain. Nonevoked pain is observed in the majority of patients with chronic injury and is a primary reason for seeking medical care. Spontaneous firing of WDR neurons is elevated in injured animals and likely reflects injury-related sensitization and possibly nonevoked pain (72, 73). Injection of A-967079 reduced “heightened” spontaneous firing of WDR neurons in inflamed rats (49). Interestingly, elevated spontaneous firing of WDR neurons in OA rats was not decreased by injection of A-967079. The differential effect of A-967079 on spontaneous firing in inflamed and OA rats was postulated to be related to the degree of inflammation on the days of neuronal recording.

5 TRPA1 Involvement in Other Diseases

5.1 Respiratory Diseases

Respiratory diseases have become a significant public health burden and unmet medical need. TRPA1 has been linked to airway sensitization, chronic cough, asthma, and Chronic Obstruction of Pulmonary Diseases (COPD) (74, 75, 76). The airways are innervated by sensory neurons that express TRPA1 in vagal and trigeminal nerves, which are responsible for transducing noxious stimuli into pain signals, and for mediating protective behaviors (sneezing, cough, and respiratory depression). A plethora of airway irritants activate TRPA1, including acrolein from cigarette smoke, ozone (air pollutants), isocyanate (industrial waste), and tear gas (chemical warfare) (56, 57). Transient TRPA1 activation by exogenous irritants evokes pain and protective reflex (sneezing, cough, and respiratory depression, avoidance), therefore providing a protective alert to eliminate exposure to irritants and limit damage to the body. However, persistent channel activation by endogenous ligands causes or aggravates existing airway irritation. Asthma, COPD, and rhinitis are associated with increased levels of reactive oxygen species (H2O2), lipid peroxidation production (e.g., 4HNE), and pro-inflammatory mediators (e.g., bradykinin and nerve growth factors) (77, 78). These agents activate TRPA1 directly (e.g., H2O2, 4HNE), indirectly (bradykinin), or increase TRPA1 surface expression (nerve growth factors). In turn, the heightened TRPA1 activity leads to the release of neurotransmitters and cytokines, further promoting neurogenic inflammation (56).

In guinea pig, aqueous extracts from cigarette smoke, acrolein, and crotonaldehyde induce neurotransmitter release, tracheal plasma extravasation, and bronchi contraction. These effects are inhibited by TRPA1 antagonist HC-030031 (56). In mice, airway exposure to oxidants (hypochlorite and H2O2) evokes respiratory depression manifested as a reduction in breathing frequency and increased end expiratory pause, which were abolished by genetic deletion (31). In an ovalbumin-induced mouse asthma model, genetic ablation and treatment with HC-030031 significantly reduced the induction of cytokines, chemokines, neurotransmitters, as well as leukocyte infiltration and airway hyperactivity (32). While these results are encouraging, many respiratory diseases are chronic, multifaceted disorders that involve inflammatory pathways. For example, asthma is associated with acute and chronic inflammation of the airway mucosa, as well as airway remodeling. Chronic obstructive pulmonary disease (COPD) is characterized by activated inflammation pathways that lead to destruction of the lung over time. It remains to be seen whether TRPA1 antagonists can alleviate symptoms and reverse disease progression in inflammatory-mediated respiratory diseases, and it is unclear whether a TRPA1 antagonist will offer more benefits than current therapies (e.g., anti-inflammatory drugs and bronchodilators) and other emerging mechanisms. Nonetheless, respiratory diseases represent an exciting frontier to be explored for TRPA1 antagonists.

5.2 Overactive Bladder

The involvement of TRPA1 in bladder activity is implied by its expression pattern and the effect of TRPA1 agonists and antagonists on bladder function. TRPA1 is expressed on C-fiber bladder afferents and urothelial cells (14, 15). The expression of TRPA1 is significantly increased in overactive bladder conditions in both rats and humans (14, 79). AITC and cinnamaldehyde increase basal bladder pressure and reduce voided volume in naive rats (15). Furthermore, injections of either a TRPA1 antisense oligodeoxynucleotide or antagonist (HC-030031) were both shown to attenuate bladder overactivity induced by spinal cord injury (79). Collectively these studies suggest that TRPA1 may be involved in bladder function under normal and pathological conditions.

5.3 Itch

Itch is a major complaint in patients with skin, kidney, diabetic, and neurological disorders (80). Ironically, many medical treatments evoke itch, limiting their clinical usage. For example, patients treated with opioids and local anesthetics frequently experience itch (81). The antimalaria drug chloroquine causes intolerable itch, which is resistant to current treatment of antihistamines. A recent study found that TRPA1 knockout mice exhibited diminished itch response to chloroquine and the endogenous pruritogen BAM8-22 (42). Since chloroquine and BAM8-22 evoke itch through two separate Mar-related G protein-coupled receptors (MrgprA3 and MrgprC11), TRPA1 may be a downstream integrator of multiple histamine-independent pathways.

Besides expression in pruritic sensory neurons, TRPA1 is detected in nonneuronal cells from human skin (12). RT-PCR and western blot demonstrated robust TRPA1 expression in primary culture of epidermal keratinocytes, melanocytes, and fibroblasts. Immunohistochemisty of human samples localized TRPA1 in the basal layer of the epidermis, dermis, and epithelium of hair follicle. These results suggest that TRPA1 expressed in the skin may directly participate in itch responses.

6 Outlook

The recent finding that a gain-of-function mutation of TRPA1 causes familial episodic pain syndrome in humans is a major milestone for TRPA1 research, establishing TRPA1 as one of two ion channels with human genetic validation for pain (55). This result, coupled with a growing preclinical literature implicating TRPA1 in multiple indications, has made TRPA1 an attractive therapeutic target. With extensive investment across the pharmaceutical industry, several novel nonreactive TRPA1 antagonist series have emerged in patents, and two TRPA1 compounds have recently advanced to human clinical trials. In February 2011, Glenmark announced the entry of the first TRPA1 antagonist into Phase I trials. GRC 17536 is reported to be highly potent (IC50  <  10 nM), selective, and orally available. It is claimed to be efficacious in inflammatory and neuropathic pain, and efficacious in airway inflammation from an asthma model. In January 2012, Cubist Pharmaceuticals/Hydra Biosciences announced entry of CB-625 into Phase I trials. CB625 is reported to be a highly potent, selective TRPA1 antagonist with efficacy in surgically induced and inflammatory mediated pain in animal models. Positive outcomes from these and other clinical trials would galvanize additional TRPA1 drug discovery efforts.


  1. 1.
    Nagatomo K, Kubo Y (2008) Caffeine activates mouse TRPA1 channels but suppresses human TRPA1 channels. Proc Natl Acad Sci USA 105(45):17373–17378PubMedCrossRefGoogle Scholar
  2. 2.
    Montell C, Birnbaumer L et al (2002) The TRP channels, a remarkably functional family. Cell 108(5):595–598PubMedCrossRefGoogle Scholar
  3. 3.
    Clapham DE (2003) TRP channels as cellular sensors. Nature 426(6966):517–524PubMedCrossRefGoogle Scholar
  4. 4.
    Story GM, Peier AM et al (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112(6):819–829PubMedCrossRefGoogle Scholar
  5. 5.
    Jordt SE, Bautista DM et al (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427(6971):260–265PubMedCrossRefGoogle Scholar
  6. 6.
    Nagata K, Duggan A et al (2005) Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. J Neurosci 25(16):4052–4061PubMedCrossRefGoogle Scholar
  7. 7.
    Obata K, Katsura H et al (2005) TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Invest 115(9):2393–2401PubMedCrossRefGoogle Scholar
  8. 8.
    Niforatos W, Zhang XF et al (2007) Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3’-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597). Mol Pharmacol 71(5):1209–1216PubMedCrossRefGoogle Scholar
  9. 9.
    Katsura H, Obata K et al (2006) Antisense knock down of TRPA1, but not TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats. Exp Neurol 200(1):112–123PubMedCrossRefGoogle Scholar
  10. 10.
    Anand U, Otto WR et al (2008) TRPA1 receptor localisation in the human peripheral nervous system and functional studies in cultured human and rat sensory neurons. Neurosci Lett 438(2):221–227PubMedCrossRefGoogle Scholar
  11. 11.
    Schmidt M, Dubin AE et al (2009) Nociceptive signals induce trafficking of TRPA1 to the plasma membrane. Neuron 64(4):498–509PubMedCrossRefGoogle Scholar
  12. 12.
    Atoyan R, Shander D et al (2009) Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. J Invest Dermatol 129(9):2312–2315PubMedCrossRefGoogle Scholar
  13. 13.
    Corey DP, Garcia-Anoveros J et al (2004) TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells. Nature 432(7018):723–730PubMedCrossRefGoogle Scholar
  14. 14.
    Du S, Araki I et al (2007) Transient receptor potential channel A1 involved in sensory transduction of rat urinary bladder through C-fiber pathway. Urology 70(4):826–831PubMedCrossRefGoogle Scholar
  15. 15.
    Streng T, Axelsson HE et al (2008) Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol 53(2):391–399PubMedCrossRefGoogle Scholar
  16. 16.
    Kondo T, Obata K et al (2009) Transient receptor potential A1 mediates gastric distention-induced visceral pain in rats. Gut 58(10):1342–1352PubMedCrossRefGoogle Scholar
  17. 17.
    Earley S, Gonzales AL et al (2009) Endothelium-dependent cerebral artery dilation mediated by TRPA1 and Ca2+  -Activated K  +  channels. Circ Res 104(8):987–994PubMedCrossRefGoogle Scholar
  18. 18.
    Cvetkov TL, Huynh KW et al (2011) Molecular architecture and subunit organization of TRPA1 ion channel revealed by electron microscopy. J Biol Chem 286(44):38168–38176PubMedCrossRefGoogle Scholar
  19. 19.
    Hinman A, Chuang HH et al (2006) TRP channel activation by reversible covalent modification. Proc Natl Acad Sci USA 103(51):19564–19568PubMedCrossRefGoogle Scholar
  20. 20.
    Macpherson LJ, Dubin AE et al (2007) Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature 445(7127):541–545PubMedCrossRefGoogle Scholar
  21. 21.
    Chen J, Zhang XF et al (2008) Molecular determinants of species-specific activation or blockade of TRPA1 channels. J Neurosci 28(19):5063–5071PubMedCrossRefGoogle Scholar
  22. 22.
    Cordero-Morales JF, Gracheva EO et al (2011) Cytoplasmic ankyrin repeats of transient receptor potential A1 (TRPA1) dictate sensitivity to thermal and chemical stimuli. Proc Natl Acad Sci USA 108(46):E1184–1191PubMedCrossRefGoogle Scholar
  23. 23.
    Doerner JF, Gisselmann G et al (2007) Transient receptor potential channel A1 is directly gated by calcium ions. J Biol Chem 282(18):13180–13189PubMedCrossRefGoogle Scholar
  24. 24.
    Zurborg S, Yurgionas B et al (2007) Direct activation of the ion channel TRPA1 by Ca2+. Nat Neurosci 10(3):277–279PubMedCrossRefGoogle Scholar
  25. 25.
    Wang YY, Chang RB et al (2008) The nociceptor ion channel TRPA1 is potentiated and inactivated by permeating calcium ions. J Biol Chem 283(47):32691–32703PubMedCrossRefGoogle Scholar
  26. 26.
    Xiao B, Dubin AE et al (2008) Identification of transmembrane domain 5 as a critical molecular determinant of menthol sensitivity in mammalian TRPA1 channels. J Neurosci 28(39):9640–9651PubMedCrossRefGoogle Scholar
  27. 27.
    Bandell M, Story GM et al (2004) Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41(6):849–857PubMedCrossRefGoogle Scholar
  28. 28.
    Escalera J, von Hehn CA et al (2008) TRPA1 mediates the noxious effects of natural sesquiterpene deterrents. J Biol Chem 283(35):24136–24144PubMedCrossRefGoogle Scholar
  29. 29.
    Bautista DM, Jordt SE et al (2006) TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 124(6):1269–1282PubMedCrossRefGoogle Scholar
  30. 30.
    Bang S, Kim KY et al (2007) Transient receptor potential A1 mediates acetaldehyde-evoked pain sensation. Eur J Neurosci 26(9):2516–2523PubMedCrossRefGoogle Scholar
  31. 31.
    Bessac BF, Sivula M et al (2008) TRPA1 is a major oxidant sensor in murine airway sensory neurons. J Clin Invest 118(5):1899–1910PubMedCrossRefGoogle Scholar
  32. 32.
    Caceres AI, Brackmann M et al (2009) A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci USA 106(22):9099–9104PubMedGoogle Scholar
  33. 33.
    Materazzi S, Nassini R et al (2008) Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1. Proc Natl Acad Sci USA 105(33):12045–12050PubMedCrossRefGoogle Scholar
  34. 34.
    Trevisani M, Siemens J et al (2007) 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci USA 104(33):13519–13524PubMedCrossRefGoogle Scholar
  35. 35.
    Andersson DA, Gentry C et al (2008) Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci 28(10):2485–2494PubMedCrossRefGoogle Scholar
  36. 36.
    Hill K, Schaefer M (2007) TRPA1 is differentially modulated by the amphipathic molecules trinitrophenol and chlorpromazine. J Biol Chem 282(10):7145–7153PubMedCrossRefGoogle Scholar
  37. 37.
    Maher M, Ao H et al (2008) Activation of TRPA1 by farnesyl thiosalicylic acid. Mol Pharmacol 73(4):1225–1234PubMedCrossRefGoogle Scholar
  38. 38.
    Matta JA, Cornett PM et al (2008) General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci USA 105(25):8784–8789PubMedCrossRefGoogle Scholar
  39. 39.
    Hu H, Tian J et al (2010) Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs. Pflugers Arch 459(4):579–592PubMedCrossRefGoogle Scholar
  40. 40.
    Ryckmans T, Aubdool AA et al (2011) Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel. Bioorg Med Chem Lett 21(16):4857–4859PubMedCrossRefGoogle Scholar
  41. 41.
    Zhang XF, Chen J et al (2008) Transient receptor potential A1 mediates an osmotically activated ion channel. Eur J Neurosci 27(3):605–611PubMedCrossRefGoogle Scholar
  42. 42.
    Wilson SR, Gerhold KA et al (2011) TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci 14(5):595–602PubMedCrossRefGoogle Scholar
  43. 43.
    Caspani O, Heppenstall PA (2009) TRPA1 and cold transduction: an unresolved issue? J Gen Physiol 133(3):245–249PubMedCrossRefGoogle Scholar
  44. 44.
    Kwan KY, Corey DP (2009) Burning cold: involvement of TRPA1 in noxious cold sensation. J Gen Physiol 133(3):251–256PubMedCrossRefGoogle Scholar
  45. 45.
    McNamara CR, Mandel-Brehm J et al (2007) TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci USA 104(33):13525–13530PubMedCrossRefGoogle Scholar
  46. 46.
    Petrus M, Peier AM et al (2007) A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain 3:40PubMedCrossRefGoogle Scholar
  47. 47.
    Eid SR, Crown ED et al (2008) HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol Pain 4:48PubMedCrossRefGoogle Scholar
  48. 48.
    Wei H, Hamalainen MM et al (2009) Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals.”. Anesthesiology 111(1):147–154PubMedCrossRefGoogle Scholar
  49. 49.
    McGaraughty S, Chu KL et al (2010) TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats. Mol Pain 6:14PubMedCrossRefGoogle Scholar
  50. 50.
    Klionsky L, Tamir R et al (2007) Species-specific pharmacology of Trichloro(sulfanyl)ethyl benzamides as transient receptor potential ankyrin 1 (TRPA1) antagonists. Mol Pain 3:39PubMedCrossRefGoogle Scholar
  51. 51.
    Chen J, Joshi SK et al (2011) Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. Pain 152(5):1165–1172PubMedCrossRefGoogle Scholar
  52. 52.
    Chen J, Lake MR et al (2007) Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient receptor potential channel A1 (TRPA1) antagonists. J Biomol Screen 12(1):61–69PubMedCrossRefGoogle Scholar
  53. 53.
    Bang S, Yoo S et al (2010) Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br J Pharmacol 161(3):707–720PubMedCrossRefGoogle Scholar
  54. 54.
    Namer B, Seifert F et al (2005) TRPA1 and TRPM8 activation in humans: effects of cinnamaldehyde and menthol. Neuroreport 16(9):955–959PubMedCrossRefGoogle Scholar
  55. 55.
    Kremeyer B, Lopera F et al (2010) A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 66(5):671–680PubMedCrossRefGoogle Scholar
  56. 56.
    Andre E, Campi B et al (2008) Cigarette smoke-induced neurogenic inflammation is mediated by alpha, beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest 118(7):2574–2582PubMedGoogle Scholar
  57. 57.
    Bessac BF, Sivula M et al (2009) Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J 23(4):1102–1114PubMedCrossRefGoogle Scholar
  58. 58.
    Kwan KY, Allchorne AJ et al (2006) TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 50(2):277–289PubMedCrossRefGoogle Scholar
  59. 59.
    Bautista DM et al (2005) Pungent products from garlic activate the sensory ion channel TRPA1. Proc Natl Acad Sci USA 102(34):12248–12252PubMedCrossRefGoogle Scholar
  60. 60.
    Kwan KY, Glazer JM et al (2009) TRPA1 modulates mechanotransduction in cutaneous sensory neurons. J Neurosci 29(15):4808–4819PubMedCrossRefGoogle Scholar
  61. 61.
    Brierley SM, Castro J et al (2011) TRPA1 contributes to specific mechanically activated currents and sensory neuron mechanical hypersensitivity. J Physiol 589(Pt 14):3575–3593PubMedCrossRefGoogle Scholar
  62. 62.
    Kerstein PC, del Camino D et al (2009) Pharmacological blockade of TRPA1 inhibits mechanical firing in nociceptors. Mol Pain 5:19PubMedCrossRefGoogle Scholar
  63. 63.
    Chen Y, Yang C et al (2011) Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 193:440–451PubMedCrossRefGoogle Scholar
  64. 64.
    Wei H, Koivisto A et al (2011) Spinal transient receptor potential ankyrin 1 channel contributes to central pain hypersensitivity in various pathophysiological conditions in the rat. Pain 152(3):582–591PubMedCrossRefGoogle Scholar
  65. 65.
    Karashima Y, Talavera K et al (2009) TRPA1 acts as a cold sensor in vitro and in vivo. Proc Natl Acad Sci USA 106(4):1273–1278PubMedCrossRefGoogle Scholar
  66. 66.
    Knowlton WM, Bifolck-Fisher A et al (2010) TRPM8, but not TRPA1, is required for neural and behavioral responses to acute noxious cold temperatures and cold-mimetics in vivo. Pain 150(2):340–350PubMedCrossRefGoogle Scholar
  67. 67.
    del Camino D, Murphy S et al (2010) TRPA1 contributes to cold hypersensitivity. J Neurosci 30(45):15165–15174PubMedCrossRefGoogle Scholar
  68. 68.
    Dunham JP, Kelly S et al (2008) Inflammation reduces mechanical thresholds in a population of transient receptor potential channel A1-expressing nociceptors in the rat. Eur J Neurosci 27(12):3151–3160PubMedCrossRefGoogle Scholar
  69. 69.
    Fajardo O, Meseguer V et al (2008) TRPA1 channels mediate cold temperature sensing in mammalian vagal sensory neurons: pharmacological and genetic evidence. J Neurosci 28(31):7863–7875PubMedCrossRefGoogle Scholar
  70. 70.
    Merrill AW, Cuellar JM et al (2008) Effects of TRPA1 agonists mustard oil and cinnamaldehyde on lumbar spinal wide-dynamic range neuronal responses to innocuous and noxious cutaneous stimuli in rats. J Neurophysiol 99(2):415–425PubMedCrossRefGoogle Scholar
  71. 71.
    Sawyer CM, Carstens MI et al (2009) Mustard oil enhances spinal neuronal responses to noxious heat but not cooling. Neurosci Lett 461(3):271–274PubMedCrossRefGoogle Scholar
  72. 72.
    Chu KL, Faltynek CR et al (2004) Increased WDR spontaneous activity and receptive field size in rats following a neuropathic or inflammatory injury: implications for mechanical sensitivity. Neurosci Lett 372:123–126PubMedCrossRefGoogle Scholar
  73. 73.
    McGaraughty S, Chu KL et al (2008) Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats. J Neurophysiol 100:3158–3166PubMedCrossRefGoogle Scholar
  74. 74.
    Bessac BF, Jordt SE (2008) Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control. Physiology (Bethesda) 23:360–370CrossRefGoogle Scholar
  75. 75.
    Simon SA, Liedtke W (2008) How irritating: the role of TRPA1 in sensing cigarette smoke and aerogenic oxidants in the airways. J Clin Invest 118(7):2383–2386PubMedGoogle Scholar
  76. 76.
    Geppetti P, Patacchini R et al (2010) Cough: the emerging role of the TRPA1 channel. Lung 188(Suppl 1):S63–68PubMedCrossRefGoogle Scholar
  77. 77.
    Dolovich J, Back N et al (1970) Kinin-like activity in nasal secretions of allergic patients. Int Arch Allergy Appl Immunol 38(4):337–344PubMedCrossRefGoogle Scholar
  78. 78.
    Winterbourn CC, Kettle AJ (2000) Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic Biol Med 29(5):403–409PubMedCrossRefGoogle Scholar
  79. 79.
    Andrade EL, Forner S et al (2011) TRPA1 receptor modulation attenuates bladder overactivity induced by spinal cord injury. Am J Physiol Renal Physiol 300(5):F1223–1234PubMedCrossRefGoogle Scholar
  80. 80.
    Verhoeven EW, Kraaimaa FW et al (2007) Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 156(6):1346–1349PubMedCrossRefGoogle Scholar
  81. 81.
    Atanassoff PG, Brull SJ et al (1999) Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res 16(4):291–298PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Abbott LaboratoriesNeuroscience Research, Global Pharmaceutical Research and DevelopmentAbbott ParkUSA

Personalised recommendations